FLNA Stock Forecast: Filana Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.64
+14.52% on the day

The median 12-month analyst price target for Filana Therapeutics, Inc. is $6.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 66 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$32.2M
Ticker Nerd rank
66/ 100
Median analyst target
$6.50
Analysts covering
2
Revenue$0.0
Operating income−$9.4M
Net income−$8.6M
Free cash flow−$3.9M
Quarterly, 7 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+49.1%
1M
−7.1%
YTD
−67.6%
1Y
−75.6%
From 52W high
−81.1%
From 52W low
+49.1%
$0.43
$3.39
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Filana Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
66/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
86
Accruals
77
Revisions
69
Volatility
68
Issuance
43
Quality
42
Momentum
26
Value
25

Growth (86): Sales and profits are climbing, and climbing faster than before.

Value (25): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

FLNA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FLNA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26FLNAHigh $8.00Median $6.50Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$5.00
Low
$6.50
Median
$8.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 May 2026Maxim GroupReinstatesBuy$5.00
6 Oct 2025LUCID CAPITAL MARKETSInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for FLNA.

Market Radar

This page is one stock. Monday covers all of them.

FLNA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

FLNA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Filana Therapeutics, Inc. returned −75.6% against +6.9% for the S&P 500, dividends included.

FLNA vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26FLNAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FLNA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.6×

Cheaper than 85% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−60.5%

Higher than 19% of US stocks

Return on assets
−21.4%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Filana Therapeutics, Inc. has a market value of $32.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$42.3M.

  • Diluted earnings per share, trailing twelve months: −$0.87.

  • Free cash flow in the twelve months to 30 June 2026: −$29.3M.

  • Shares outstanding: 48.3M.

  • Filana Therapeutics, Inc. employs 17 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

FLNA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FLNAFilana Therapeutics, Inc.$32.2M66
CRBUCaribou Biosciences, Inc.$30.5M43
HYPDHyperion DeFi, Inc.$31.5M39
HYFTMindWalk Holdings Corp.$32.0M44
GRDXGridAI Technologies Corp.$32.4M16
NXTCNextCure, Inc.$29.5M43
ATNMActinium Pharmaceuticals, Inc.$32.9M87

Take a look at FLNA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Filana Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about FLNA

What is the FLNA stock price forecast for 2026-2027?

The median 12-month analyst price target for Filana Therapeutics, Inc. is $6.5, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FLNA stock a buy right now?

Of the 2 analysts covering Filana Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Filana Therapeutics, Inc. 66 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FLNA?

As at 21 Nov 2026, Filana Therapeutics, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).

Will FLNA stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $6.5, and Ticker Nerd's factor model ranks Filana Therapeutics, Inc. 66 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FLNA stock forecast for 2030?

No analyst covering Filana Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FLNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.

How has FLNA stock performed over the past year?

Filana Therapeutics, Inc. returned -75.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Filana Therapeutics, Inc. do?

Filana Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing investigational therapies for central nervous system disorders. The company’s current work centers on simufilam, an oral small-molecule candidate being studied for TSC-related epilepsy and other neurological conditions linked to filamin A, along with SavaDx, an early-stage blood-based diagnostic program designed to detect Alzheimer’s disease.

Company

About Filana Therapeutics, Inc.

Filana Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing investigational therapies for central nervous system disorders. The company’s current work centers on simufilam, an oral small-molecule candidate being studied for TSC-related epilepsy and other neurological conditions linked to filamin A, along with SavaDx, an early-stage blood-based diagnostic program designed to detect Alzheimer’s disease. Based in Austin, Texas, Filana Therapeutics operates in the biotechnology sector with a research-driven model built around drug development and biomarker discovery. Its programs target complex brain disorders where new treatment and diagnostic options remain limited, positioning the company as a specialized participant in the neuroscience and precision-medicine landscape.

CEO Mr. Richard Jon Barry · 17 employees · United States · https://www.filanatx.com